Morningstar

Vanda Pharmaceuticals Rises on FDA Biologics License Application

Provided by Dow Jones Dec 15, 2025, 5:39:00 PM

By Elias Schisgall

Vanda Pharmaceuticals shares rose after the company said it had submitted a biologics license application to the Food and Drug Administration for its generalized pustular psoriasis treatment.

The stock was up 7.3% to $6.69 midday Monday. Shares have gained nearly 40% this year.

The company said its application, for imsidolimab, was supported by positive results from two global Phase 3 studies that saw a single dose lead to rapid disease clearance for patients with GPP, a rare and serious autoinflammatory skin disorder.

Vanda has requested priority review for its application, it said.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

December 15, 2025 12:39 ET (17:39 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

What’s Ahead for Stocks This Quarter—and Where to Invest

Morningstar’s chief market strategist and economist share their outlooks for the fourth quarter of 2026.

David Sekera, CFA, Preston Caldwell, and Susan Dziubinski Oct 15, 2026

5 Stocks to Sell for Tax-Loss Harvesting

Plus, earnings season kicks off with big banks.

David Sekera, CFA and Sarah Hansen Oct 12, 2026

Are TIPS ETFs the Best Way to Fight Inflation?

Plus, four TIPS ETFs with top marks from Morningstar, and what you need to know before investing.

Daniel Sotiroff and Ivanna Hampton Oct 16, 2026

33 Undervalued Stocks to Buy Before the Market Shifts Again

Here’s the new list of Morningstar’s top analyst picks for the fourth quarter of 2026.

Susan Dziubinski and Tori Brovet Oct 12, 2026

Ask the Analyst: What Is the Best Source for Low-Risk Tax-Free Income?

Even short-term muni funds aren’t totally immune from losses.

Amy C. Arnott, CFA Oct 13, 2026

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.